Newsroom

TENGCHONG, China--(BUSINESS WIRE)--El Foro de Científicos de Tengchong 2025 se inauguró el sábado en la provincia de Yunnan, al suroeste de China, y reunió a destacados científicos y figuras académicas para explorar la innovación en campos de vanguardia, como la inteligencia artificial, la biodiversidad y la tecnología cuántica. Entre los participantes más destacados se encuentran el premio nobel de física Konstantin Novoselov; Efim Zelmanov, galardonado con la Medalla Fields, y el ganador del...

TENGCHONG, China--(BUSINESS WIRE)--Das Tengchong Scientists Forum 2025 öffnete am Samstag in der südwestchinesischen Provinz Yunnan seine Pforten und versammelt führende Wissenschaftler und Akademiker, um Innovationen in Grenzbereichen wie künstlicher Intelligenz, Biodiversität und Quantentechnologie zu untersuchen. Zu den prominenten Teilnehmern gehören der Nobelpreisträger für Physik, Konstantin Novoselov, der Fields-Medaillengewinner Efim Zelmanov und der Turing-Preisträger Andrew Chi-Chih Y...

MEMPHIS, Tenn.--(BUSINESS WIRE)--The spirit of Memphis was on full display this weekend as tens of thousands of runners, patient families, doctors, researchers, support staff, and volunteers came together for the 2025 St. Jude Memphis Marathon® Weekend presented by Juice Plus+®. In its 24th year, the event raised nearly $16 million, transforming the city into a celebration of courage, community and hope, all to benefit the lifesaving mission of St. Jude Children’s Research Hospital®. From the e...

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Klarna Group plc (NYSE: KLAR) resulting from allegations that Klarna may have issued materially misleading business information to the investing public. So What: If you purchased Klarna securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Ro...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and adolescents living with hemophilia A or B with inhibitors. The results demonstrated the superiority of HYMPAVZI in improving key bleeding outcomes compared to on-demand (OD) treatment with bypassing agents. HYMPAVZI was administered with a straightforward, once-weekly subcutaneous injection requiring minimal preparation and no tr...

MIAMI--(BUSINESS WIRE)--TheOther, a premium matcha brand sourcing ceremonial-grade, first harvest matcha from Uji, Japan, made its official debut during Art Basel with an intimate multi-sensory dinner last night at Forte Dei Marmi followed by a private after party at SOPRA Club in Miami Beach. Co-hosted by British Rapper Central Cee, the evening celebrated TheOther Master’s Blend, a first-harvest matcha crafted in collaboration with one of Japan’s most respected tea-growing lineages, spanning o...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ongoing Phase 1/2 multidose study of VGA039 in von Willebrand disease (VWD). The data are being presented in an oral session at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida. VGA039 is a first-in-class monoc...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #265) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. Both KITE-753 and...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data are being presented during an oral presentation at the 67th American Society o...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refractory multiple myeloma (RRMM) patients who had received at least three prior lines of therapy. These new...